Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla: Clinical Trials & FDA Approval Profile

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 7 active protocols (1 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)60 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)7 (1)
Completed vs Stopped Early3 / 1 (6.3%)
Median Closed Actual Enrollment60 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hospital Research SiteLocationShared Protocols
Hospital Universitario Virgen del RocíoSeville8
Hospital del MarBarcelona4
Hospital Universitario Virgen de las NievesGranada, Granada4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05325593Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune ThrombocytopeniaPhase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Fundación Pública Andaluza para la gestión de la Investigación en Sevilla Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI